Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://puffla034383.opentechblog.com/61485495/retatrutide-australia-a-new-hope-for-losing-weight